(Q63317790)
Statements
A Phase 1 Randomized, Placebo-controlled, Dose-escalation Study to Evaluate the Safety of MEDI4212 in Subjects With IgE >= 30 IU/mL (English)
0 references
January 2012
0 references
June 2013
0 references
295
0 references
18 year
0 references
60 year
0 references